Drug Trial Radar · NCT00387088
Tiotropium / Respimat One Year Study in COPD.
Last checked: Nov 20, 2026Latest source record: May 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,991
Actual
Start
Sep 2006
Primary completion
Jan 2009
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Oct 12, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Model
- Parallel
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to evaluate the long-term (one year) efficacy and safety of tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study will examine the effect of treatment on COPD exacerbations.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
RespimatDevice
TiotropiumDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337Time frame: Baseline and Day 337
- Time to First Chronic Obstructive Pulmonary Disease (COPD) ExacerbationTime frame: During actual study treatment period (planned Day 1 to Day 337)
Locations
334 sites in 31 countries. Site status is shown where the registry gives one.
205.372.01012 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.372.01020 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
205.372.01062 Boehringer Ingelheim Investigational Site
Mobile, Alabama
205.372.01048 Boehringer Ingelheim Investigational Site
Berkeley, California
205.372.01037 Boehringer Ingelheim Investigational Site
Huntington Park, California
205.372.01058 Boehringer Ingelheim Investigational Site
Long Beach, California
205.372.01059 Boehringer Ingelheim Investigational Site
Long Beach, California
205.372.01007 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.372.01034 Boehringer Ingelheim Investigational Site
Los Angeles, California
205.372.01028 Boehringer Ingelheim Investigational Site
Rancho Mirage, California
205.372.01011 Boehringer Ingelheim Investigational Site
San Diego, California
205.372.01066 Boehringer Ingelheim Investigational Site
Boulder, Colorado
205.372.01008 Boehringer Ingelheim Investigational Site
Norwalk, Connecticut
205.372.01004 Boehringer Ingelheim Investigational Site
Brandon, Florida
205.372.01060 Boehringer Ingelheim Investigational Site
Clearwater, Florida
205.372.01069 Boehringer Ingelheim Investigational Site
Miami Beach, Florida
205.372.01023 Boehringer Ingelheim Investigational Site
West Palm Beach, Florida
205.372.01053 Boehringer Ingelheim Investigational Site
Winter Park, Florida
205.372.01045 Boehringer Ingelheim Investigational Site
Calhoun, Georgia
205.372.01043 Boehringer Ingelheim Investigational Site
Normal, Illinois
205.372.01061 Boehringer Ingelheim Investigational Site
Dubuque, Iowa
205.372.01035 Boehringer Ingelheim Investigational Site
Wichita, Kansas
205.372.01049 Boehringer Ingelheim Investigational Site
Shreveport, Louisiana
205.372.01015 Boehringer Ingelheim Investigational Site
Biddeford, Maine
205.372.01067 Boehringer Ingelheim Investigational Site
Columbia, Maryland
205.372.01006 Boehringer Ingelheim Investigational Site
Rockville, Maryland
205.372.01013 Boehringer Ingelheim Investigational Site
Detroit, Michigan
205.372.01003 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
205.372.01021 Boehringer Ingelheim Investigational Site
Chesterfield, Missouri
205.372.01014 Boehringer Ingelheim Investigational Site
St Louis, Missouri
205.372.01036 Boehringer Ingelheim Investigational Site
Omaha, Nebraska
205.372.01046 Boehringer Ingelheim Investigational Site
Albuquerque, New Mexico
205.372.01024 Boehringer Ingelheim Investigational Site
Mineola, New York
205.372.01029 Boehringer Ingelheim Investigational Site
Rochester, New York
205.372.01030 Boehringer Ingelheim Investigational Site
Syracuse, New York
205.372.01026 Boehringer Ingelheim Investigational Site
Chapel Hill, North Carolina
205.372.01019 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina
205.372.01027 Boehringer Ingelheim Investigational Site
Elizabeth City, North Carolina
205.372.01038 Boehringer Ingelheim Investigational Site
Raleigh, North Carolina
205.372.01031 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
Showing 40 of 334 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.